<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453735</url>
  </required_header>
  <id_info>
    <org_study_id>REK 54041</org_study_id>
    <nct_id>NCT04453735</nct_id>
  </id_info>
  <brief_title>MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study</brief_title>
  <official_title>MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are cornerstone treatment in secondary cardiovascular disease (CVD) prevention.&#xD;
      Today, statin non-adherence (patients not taking their prescribed drug) remains a major&#xD;
      public health concern, leading to adverse outcomes in terms of morbidity, mortality and&#xD;
      healthcare costs. The principal reason for statin non-adherence and discontinuation is&#xD;
      statin-associated muscle symptoms (SAMS). Objective SAMS diagnostics do not exist. We aim to&#xD;
      unravel the pathophysiology of SAMS and develop diagnostic tools to differentiate real SAMS&#xD;
      from muscle symptoms not related to the statin, among coronary patients with self-perceived&#xD;
      SAMS. In this follow-up study we aims to determine the effect of 7 weeks open treatment with&#xD;
      atorvastatin 40 mg/day, followed by 7 weeks open treatment with no lipid lowering treatment,&#xD;
      on muscle symptom intensity in patients classified with confirmed statin-associated muscle&#xD;
      symptoms (SAMS) (i.e. statin-dependent muscle side-effects) and non-SAMS in the MUscle&#xD;
      Side-Effects of atorvastatin in coronary patients (MUSE) randomized double blinded cross-over&#xD;
      trial.&#xD;
&#xD;
      We have developed novel methods that will be used to measure atorvastatin metabolites and&#xD;
      drug effect biomarkers directly in skeletal muscle and blood . The diagnostic accuracy of&#xD;
      these biomarkers to differentiate real SAMS from non-SAMS will be evaluated. A new diagnostic&#xD;
      tool may potentially be implemented to assess SAMS in the individual patient and enable&#xD;
      personalized follow-up. It may also represent an important tool in the communication with&#xD;
      patients misattributing their muscle symptoms to statins. The long-term results may be better&#xD;
      quality of life and reduced morbidity, mortality and healthcare costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, open, intervention study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual mean difference in muscular symptom intensity measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score between treatment periods with statin and &quot;no statin treatment&quot;</measure>
    <time_frame>16 weeks following study start</time_frame>
    <description>Individual mean difference in muscular symptom (i.e. pain, aching, tenderness, stiffness, cramp and/or weakness) intensity between treatment periods with statin and no statin, reported by the patients over the last three weeks (i.e. week 4-7) measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score with aggregated data from each subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who report muscle symptoms on atorvastatin treatment and not on statin (dichotomous Statin Associated Muscle Symptom classification)</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin-related variables in muscle and the primary study endpoint. The ability of atorvastatin-related variables in muscle to differentiate confirmed SAMS and non-SAMS</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin-related variables in plasma vs. muscle and PBMC vs. muscle. Correlation between atorvastatin-related variables in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin: HMGCR in muscle and the primary study endpoint. The ability of atorvastatin:HMGCR in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin:HMGCR in PBMC vs. muscle. Correlation between atorvastatin:HMGCR in PBMC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mevalonate pathway intermediates in muscle and the primary study endpoint. The ability of mevalonate pathway intermediates in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mevalonate pathway intermediates in plasma vs. muscle and PBMC vs. muscle. Correlation between mevalonate pathway intermediates in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mitochondrial respiratory enzymes in muscle and the primary study endpoint. The ability of mitochondrial respiratory enzymes in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mitochondrial respiratory enzymes in PBMC vs. muscle. Correlation between mitochondrial respiratory enzymes in PMBC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the FKBP1A:RyR1 ratio in muscle and the primary study endpoint. The ability of the FKBP1A:RyR1 ratio in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the FKBP1A:RyR1 ratio in PBMC vs. muscle. Correlation between the FKBP1A:RyR1 ratio in PBMC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between caspase 3 signalling in muscle and the primary study endpoint. The ability of caspase 3 signalling in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between caspase 3 signalling in PBMC vs. muscle. Correlation between caspase 3 signalling in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in muscle response variables between atorvastatin period and non-statin period.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of molecular effects in blood vs. muscle. Difference in blood response variables between atorvastatin period and non-statin period. Correlation between atorvastatin-related variables and response variables in blood.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin adherence measured with indirect methods and by parent drug and metabolite concentrations in blood</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset CHD symptoms. Intolerable muscle symptoms leading to discontinuation from the treatment arm. Creatine kinase (CK) &gt; 10 times upper limit of the normal range or alaninaminotransferase (ALT) &gt; 3 times upper normal limit</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Statin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin mylan 40 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No statin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin mylan 40 Mg Oral Tablet</intervention_name>
    <description>Oral tablet on regular prescription</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in the MUSE trial (Eudract nr. 2018-004261-14) and still fulfilling the&#xD;
             study entry criteria: First or recurrent diagnosis (myocardial infarction) or&#xD;
             treatments (PCI or CABG) for a CHD event 12-42 months prior to study start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a&#xD;
             CHD event the a) past 12 months prior to study start in high risk patients (i.e. at&#xD;
             least one of following comorbid conditions: systolic heart failure, &gt;1 previous&#xD;
             myocardial infarction, kidney failure, diabetes, and smokers) and b) the past 6 months&#xD;
             prior to study start in low risk patients without any of the co-morbid conditions&#xD;
             mentioned above and in patients who are not taking a statin at all.&#xD;
&#xD;
          -  Patients with symptomatic peripheral artery disease and patients with familial&#xD;
             hypercholesterolemia&#xD;
&#xD;
          -  Patient has any contraindications for atorvastatin listed in the Summary of Product&#xD;
             Characteristics (i.e. known hypersensitivity to the ingredients, acute liver failure/&#xD;
             ALT &gt; 3 times upper limit of the normal range in blood at study start, pregnancy and&#xD;
             breastfeeding )&#xD;
&#xD;
          -  History of previous rhabdomyolysis, myopathy or liver failure due to statin treatment&#xD;
             with CK &gt; 10 times upper limit of the normal range or ALT &gt; 3 times upper limit of the&#xD;
             normal range.&#xD;
&#xD;
          -  Any condition (e.g. psychiatric illness, dementia) or situation, that in the&#xD;
             investigator's opinion could put the subject at significant risk, confound the study&#xD;
             results, interfere significantly with the subject participation in the study, or&#xD;
             rendering informed consent unfeasible&#xD;
&#xD;
          -  Short life expectancy (&lt;12 months) due to other medical conditions&#xD;
&#xD;
          -  Not being able to understand Norwegian.&#xD;
&#xD;
          -  Women of childbearing potential defined as all premenopausal female.&#xD;
&#xD;
          -  Participation in another randomized clinical trial&#xD;
&#xD;
          -  Classified with significantly more muscle symptoms on placebo than on atorvastatin in&#xD;
             the MUSE trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vestre Viken HF, Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Buskerud</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Vestfold</name>
      <address>
        <city>TÃ¸nsberg</city>
        <state>Vestfold</state>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data will be made available for other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available within 5 years of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

